Ketamine for alcohol addiction granted UK fast-track designation
Psychedelichealth - 7th February 2023
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its patented Ketamine-Assisted Psychotherapy for the treatment of Severe Alcohol Use Disorder.
The passport was granted under the UK's Innovative Licensing and Access Pathway (ILAP). ILAP aims to speed up time to market and provide access to expert advice from the MHRA and its partners, including the National Institute of Health and Care Excellence (NICE).
https://psychedelichealth.co.uk/2023/02/07/ketamine-alcohol-addiction-uk-fast-track/
